MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtct.2026.09.047

Медицинская библиотека · Transplantation and cellular therapy · 2026

Impact of Prophylactic Steroids on CAR T-cell Related Toxicity for Relapsed and Refractory Non-Hodgkin Lymphoma.

Habib Alma, Youssef Youssef, Welkie Rina Li, Butman Jacob, Bond David A, Sawalha Yazeed, Sigmund Audrey, Reneau John C, Alinari Lapo, Song No-Joon, Chan Wing, Krull Jordan, Rubinstein Mark P, Hanel Walter, Christian Beth, Baiocchi Robert A, Maddocks Kami, Brammer Jonathan, Sanchez-Pettito Gabriela, Shindiapina Polina, Choe Hannah, Wang Jiasheng, Voorhees Timothy J, Freud Aharon G, Vasu Sumithira, Wall Sarah, de Lima Marcos, Denlinger Nathan

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Anti-CD19 chimeric antigen receptor T-cell therapy (CAR-T) has transformed the treatment of relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). However, toxicities including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) remain significant. Prophylactic corticosteroid use increased after cohort 6 of ZUMA-1, which suggested reduced severe CRS and ICANS, although the lack of a comparator arm limits interpretation.

OBJECTIVE

To evaluate the impact of steroid prophylaxis on outcomes and toxicities in a real-world setting.

STUDY

DESIGN

We conducted a retrospective, single-institution analysis of adults (≥18 years) with R/R NHL treated with CD28 costimulated axicabtagene ciloleucel (axi-cel) or brexucabtagene autoleucel (brexu-cel) at The Ohio State University (2018-2023). All patients received steroid prophylaxis (dexamethasone 10 mg daily × 3 from infusion day). Outcomes including toxicities (CRS, ICANS) and response rates, survival outcomes, and hazard ratios were compared using logistic regression, log-rank test, and Cox model.

RESULTS

137 patients received CAR-T (axi-cel n=118, brexu-cel n=19); 27.0% received steroid prophylaxis (PPX). Baseline characteristics were similar between groups, although primary refractory disease differed. CRS and ICANS prevalence did not significantly differ between cohorts. Any-grade CRS occurred in 97.3% of patients with PPX vs 88.0% with no PPX (p=0.13), with grade 3-4 CRS in 2.7% vs 12.0% (p=0.13). ICANS occurred in 75.7% vs 68.0% (p=0.38), with grade 3-4 ICANS in 24.3% vs 32.0% (p=0.38). Median time to CRS onset was delayed in the PPX group (4 vs 3 days, p<0.01), with no difference in ICANS onset. Overall response rates (ORR) were 75.7% vs 69.0% (p=0.44); complete response rates (CRR) were 62.2% vs 54.0% (p=0.39). OS and PFS did not differ.

CONCLUSION

Prophylactic corticosteroids did not impact CRS, ICANS, response rates, or survival. Although CRS onset may be modestly delayed, these findings do not support routine steroid prophylaxis in CAR-T-treated NHL patients.

Для цитирования: Habib Alma, Youssef Youssef, Welkie Rina Li, Butman Jacob, Bond David A, Sawalha Yazeed, Sigmund Audrey, Reneau John C, Alinari Lapo, Song No-Joon, Chan Wing, Krull Jordan, Rubinstein Mark P, Hanel Walter, Christian Beth, Baiocchi Robert A, Maddocks Kami, Brammer Jonathan, Sanchez-Pettito Gabriela, Shindiapina Polina, Choe Hannah, Wang Jiasheng, Voorhees Timothy J, Freud Aharon G, Vasu Sumithira, Wall Sarah, de Lima Marcos, Denlinger Nathan. Impact of Prophylactic Steroids on CAR T-cell Related Toxicity for Relapsed and Refractory Non-Hodgkin Lymphoma.. Transplantation and cellular therapy. 2026. DOI: 10.1016/j.jtct.2026.09.047.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.